RPL17 and non-small cell lung carcinoma: Finally, we correlated enhanced monocyte frequencies before therapy initiation with clinical response and could show association with lower hazard, extended progression-free and overall survival.b) Monitoring the immune response in non small cell lung cancer patients refractory to anti-PD-1 immunotherapy treated with a novel combination immunotherapy of anti-PD-1 and an IL-15 superagonist.